Item
1.01 Entry Into a Material Definitive Agreement.
On
June 16, 2020, Actinium Pharmaceuticals, Inc. (the “Company”) commenced a public offering (the “Offering”)
of its common stock, par value $0.001 per share (the “Common Stock”) or Common Stock equivalents in
lieu thereof. Subsequently, on June 16, 2020, the Company announced the pricing of the Offering of an aggregate of 76,923,077
shares of Common Stock (or Common Stock equivalents in lieu thereof ) at a public offering price of $0.3250 per share. The Offering
was made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-216748) initially filed with the
Securities and Exchange Commission (the “Commission”) on March 16, 2017, as subsequently amended and
declared effective by the Commission on October 12, 2017. A preliminary prospectus supplement and final prospectus supplement
and the accompanying prospectus relating to the Offering have been filed with the Commission.
In
the Offering, the Company will issue up to an aggregate of 55,653,846 shares of Common Stock (the “Shares”)
and pre-funded warrants (the “Pre-funded Warrants”) to purchase up to 21,269,231 shares of Common Stock,
at an exercise price of $0.0001 per share. The Pre-funded Warrants will be sold at $0.3249 per Pre-Funded Warrant. The Pre-Funded
Warrants will be immediately exercisable and may be exercised at any time after their original issuance until such Pre-funded
Warrants are exercised in full. A holder of a Pre-funded Warrant may not exercise any portion of such holder’s Pre-funded
Warrants to the extent that the holder would own more than 4.99% (or, at the election of the holder, 9.99%) of the Company’s
outstanding shares of Common Stock immediately after exercise, except that upon at least 61 days’ prior notice from the
holder to the Company, the holder may increase the amount of ownership of outstanding shares of Common Stock after exercising
the holder’s Pre-funded Warrants up to 9.99% of the number of shares of Common Stock outstanding immediately after giving
effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-funded Warrants.
The
net proceeds to the Company from the Offering are expected to be approximately $22.8 million, after deducting placement agent
fees and estimate offering expenses payable by the Company. The Company anticipates using the net proceeds from the Offering to
complete its ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate Iomab-B, prepare and submit a Biologics License
Application to the U.S. Food and Drug Administration and Marketing Authorization Application to the European Medicines Agency,
as well as commercialization activities for Iomab-B in the United States. The Company will also use the net proceeds to progress
Phase 1 trials for its refocused CD33 program to the proof of concept stage, to support its AWE Technology Platform, Iomab-ACT
program and research and development and for general working capital needs. The Offering is expected to close on or about June
19, 2020, subject to satisfaction of customary closing conditions.
In
connection with the Offering, on June 17, 2020, the Company entered into a securities purchase agreement (the “Purchase
Agreement”) with certain institutional investors in the Offering. In the Purchase Agreement, the Company agreed
not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or
any securities convertible into or exercisable or exchangeable for Common Stock for a period of 30 days following the closing
of the Offering. In addition, the Company agreed not to effect or enter into an agreement to effect any issuance of Common Stock
or common stock equivalents involving a variable rate transaction, as defined in the Purchase Agreement, for a period of six months
following the closing of the Offering, subject to certain exceptions.
H.C. Wainwright & Co., LLC (“Wainwright”)
served as our exclusive lead placement agent on a reasonable best efforts basis in connection with the Offering, pursuant to that
engagement letter, dated as of June 15, 2020, between the Company and Wainwright (the “Engagement Letter”).
Pursuant to the Engagement Letter, the Company will pay the placement agents a cash fee of 7.0% of the aggregate gross proceeds
of the Offering and reimburse Wainwright for a non-accountable expense allowance of $25,000, clearing expense of $12,900 and up
to $100,000 in legal fees.
The
Engagement Letter and the Purchase Agreement contain customary representations and warranties, agreements and obligations, conditions
to closing and termination provisions.
The
legal opinion of Haynes and Boone, LLP relating to the legality of the issuance and sale of the Shares, the Pre-Funded Warrants
and shares of Common Stock underlying the Pre-Funded Warrants is attached as Exhibit 5.1 to this Current Report on Form 8-K.
The
foregoing descriptions of terms and conditions of the Purchase Agreement and the Pre-funded Warrants do not purport to be complete
and are qualified in their entirety by the full text of the form of the Purchase Agreement and the form of Pre-funded Warrant,
which are attached hereto as 10.1 and 4.1, respectively.